CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	[1]
Current assets:
Cash and cash equivalents	$ 282,890	$ 246,487
Related party receivables from collaborative arrangements	88,974	93,931
Prepaid expenses and other current assets	1,069	1,640
Total current assets	372,933	342,058
Property and equipment, net	24	28
Equity and long-term investments	519,325	438,258
Capitalized fees paid to a related party, net	121,797	125,253
Deferred tax assets, net	74,023	93,759
Other assets	188	214
Total assets	1,088,290	999,570
Current liabilities:
Accounts payable	14	66
Accrued personnel-related expenses	652	490
Accrued interest payable	1,668	4,152
Other accrued liabilities	1,470	1,402
Total current liabilities	3,804	6,110
Long-term debt, net of discount and issuance costs	387,728	385,517
Other long-term liabilities	77	106
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 101,408 and 101,392 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	1,014	1,014
Additional paid-in capital	1,261,326	1,260,900
Accumulated deficit	(627,879)	(722,002)
Total Innoviva stockholders' equity	634,461	539,912
Noncontrolling interest	62,220	67,925
Total stockholders' equity	696,681	607,837
Total liabilities and stockholders' equity	$ 1,088,290	$ 999,570

[1] Consolidated balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements.